

## Stahl's Illustrated

## Index

A $\beta$  and A $\delta$  fibers, 13, 33  
 action potential, of nociceptive signal, 19  
 activity-dependent nociception, in pain pathways, 19  
 acupuncture, 120  
 acute pain: and analgesic effects from opiates, 83; definition of, 20; difference between chronic pain and, 21; and nociceptive pain, 22–23  
 adjuvants, and drugs, 119  
 aerobic exercise, 129  
 affective spectrum disorder, and fibromyalgia, 62–63  
 allodynia, 26, 33, 48  
 alpha 1 adrenergic receptor blockade, 88  
 alpha 2 delta ligands, 90–95. *See also* gabapentin; pregabalin  
 alternative treatments, and drugs, 120  
 American College of Rheumatology (ACR), 58–59  
 amitriptyline, 89  
 amoxapine, 89  
 amphetamines, 119  
 amygdala, 18, 60. *See also* brain  
 analgesia, and effects of opiates, 83  
 anandamide (endogenous cannabinoid), 44  
 anticonvulsants: actions of, 107; off-label use of for neuropathic pain, 118;

overview of, 106. *See also* carbamazepine; gabapentin; lamotrigine; oxcarbazepine; phenytoin; pregabalin; topiramate; zonisamide  
 antidepressants, 54–55, 73. *See also* tricyclic antidepressants  
 antihistamines, 119  
 anti-nuclear antibody (ANA), 52  
 anxiety disorders: and fibromyalgia, 61, 63, 66; limbic pathway and emotional component of pain, 18; pain as symptom of, 77–78; and pregabalin, 94; and temporomandibular joint disorder, 75. *See also* generalized anxiety disorder  
 back pain: and changes in brain structure, 40, 42, 43; and chronic low-back pain as pain disorder, 72; cost of healthcare for, 7; and fibrofog, 42; and topiramate, 114; and tricyclic antidepressants, 87  
 baclofen, 74, 118  
 balneotherapy, 129  
 biofeedback, 129  
 bipolar disorder, and fibromyalgia, 66  
 botulinum toxin, 120  
 bradykinin (BK) and bradykinin 2 (B2) receptors, 15

brain, chronic pain and changes in, 40–43. *See also* amygdala; dorsolateral prefrontal cortex; neurobiology; periaqueductal gray  
 brainstem, 17

caffeine, 119

cannabinoids and cannabis, 44, 119

capsaicin, 73, 120

carbamazepine, 74, 108–109

caretakers, and impact of pain, 5

central nervous system, and diagnosis of pain disorders, 57. *See also* central sensitization

central pain, clinical differences between peripheral pain and, 24

central sensitization: and alpha 2 delta ligands, 90, 91; and anticonvulsants, 107; and excessive nociceptive activity, 31; and fibromyalgia, 58; and increase in painful symptoms, 34–36. *See also* central nervous system

C-fibers, 13, 33

chondroitin sulfate, 120

chronic low-back pain. *See* back pain

chronic pain: association of with psychiatric disorders, 24; and central sensitization, 34; and changes in brain, 40–43; communication and treatment of, 130; definition of, 20; difference between acute pain and, 21; non-pharmaceutical adjunct treatments for, 129; opiates for maintenance treatment of, 84; and posttraumatic stress disorder in veterans, 79

chronic pelvic pain, 76

chronic widespread pain, and fibromyalgia, 68

cognitive behavioral therapy (CBT), 129

cognitive function: and duloxetine, 98; and fibromyalgia, 65; and reduction of gray matter in chronic pain, 42. *See also* fibrofog

communication, and treatment of chronic pain, 130

complete blood count with differential (CBC), 52

complex regional pain syndrome (CRPS), 70

cost, of pain to healthcare system, 7

C-reactive protein (CRP), 52

cyclooxygenase-inhibiting nitric oxide donating drugs (CINODs), 86

cyclooxygenase (COX)-2 inhibitors, 86

CYP450 2D6 inhibitor, 102

daily living activities, impact of pain on, 4, 69

deep sleep, 64

dependence, and long term effects of opiates, 84

depression: prevalence of pain comorbid with, 4; and temporomandibular joint disorder, 75. *See also* major depressive disorder

desipramine, 89

desvenlafaxine, 104–105

diabetic peripheral neuropathic pain (DPNP), 69, 98, 114

diabolical learning models, 38–39

diagnosis, of fibromyalgia, 58–59. *See also* patients

directed history, 50

disability, and impact of chronic or recurrent pain, 2, 4, 5, 6, 9. *See also* impairments

discriminatory pathway, 17

dorsal horn: and nociception, 15–17; and segmental central sensitization, 35

dorsal root ganglion, 13

dorsolateral prefrontal cortex (DLPFC), and fibromyalgia, 65

doxepin, 89

drugs: and adjuvants, 119; and alternative treatments, 120; and communication with patient, 130; and complex regional pain syndrome, 70; efficacy of various and hypotheses on

- neurologic basis of neuropathic pain, 45; and off-label neuropathic agents, 118; overview of, 81. *See also* alpha 2 delta ligands; anticonvulsants; antidepressants; lidocaine; non-steroidal anti-inflammatory drugs; norepinephrine reuptake inhibitors; opiates; serotonin norepinephrine reuptake inhibitors; side effects
- drug mechanism hypotheses, for neurobiologic basis of neuropathic pain, 45
- duloxetine, 71, 98–99
- ectopic activity, and peripheral sensitization, 32–33
- education, and treatment of chronic pain, 129
- electrolyte panel, 52
- emotional/motivational pathway, 17–18
- endocannabinoid deficiency hypothesis, 44
- ephaptic cross-talk, and peripheral sensitization, 33
- epidemiology. *See* prevalence
- erythrocyte sedimentation rate (ESR), 52
- eslicarbazepine, 110
- excessive nociceptive activity, and central sensitization, 31
- family, and impact of pain, 5
- fatigue, and fibromyalgia, 60
- fibrofog, 60, 65
- fibromyalgia: as affective spectrum disorder, 62–63; and alpha 2 delta ligands, 94, 96; and cannabinoids, 44; and changes in brain, 40, 43; as cognitive disorder, 65; comorbidity with mood and anxiety disorders, 18, 61, 63, 66; and descriptive terms for pain, 48; diagnosis of, 58–59; and duloxetine, 98; etiology of, 61; impairment and symptoms of, 60; and milnacipran, 100; and serotonin norepinephrine reuptake inhibitors, 96; as sleep disorder, 64
- gabapentin, 74, 90, 92–93
- gender, and diagnosis of fibromyalgia, 59, 67–68
- generalized anxiety disorder: and duloxetine, 98; and fibromyalgia, 62. *See also* anxiety disorders
- glucosamine, 120
- gray matter, and chronic pain, 41–43. *See also* periaqueductal gray
- headaches: and cannabinoids, 44; and changes in brain structure, 40; and trigeminal neuralgia, 74. *See also* migraines
- herpes zoster virus, 73
- histamine 1 (H1) receptor, 15, 88
- hyperalgesia: and cannabinoids, 44; definition of, 25; and ephaptic cross-talk in peripheral sensitization, 33; and inflammatory pain, 28
- hypnotherapy, 129
- hypothalamus, 60
- impairments, and symptoms of fibromyalgia, 60. *See also* disability
- inflammatory pain, and hyperalgesia, 28
- integrated care system, 128
- irritable bowel syndrome, 40, 43, 44
- ketamine, 121
- laboratory tests, 52
- lamotrigine, 74, 112–13
- learning, and “un-learning” of pain, 38–39
- legal issues, in pain treatment, 124
- levetiracetam, 118
- licarbazepine, 110
- lidocaine, 14, 73, 85, 121
- lifestyle, impact of pain on, 1, 4. *See also* daily living activities

limbic pathways, 17–18  
 locus coeruleus, 29

major depressive disorder: and desvenlafaxine, 104; and duloxetine, 98; and fibromyalgia, 62, 66; pain as symptom of, 78. *See also* depression  
 medical care: and cost of pain, 7; pain as reason for seeking, 3; and physical examination of patient, 51. *See also* laboratory tests; treatment  
 meditation, as alternative treatment, 120  
 methadone, 121  
 migraines, 43, 114. *See also* headaches  
 milnacipran, 100–101  
 mixed pain, compared to central and peripheral pain, 24  
 mood disorders: and fibromyalgia, 18, 63, 66; limbic pathway and emotional component of pain, 61; pain as symptom of, 77–78. *See also* depression  
 multiple sclerosis (MS), 74  
 muscarinic M1 and M3 receptor blockade, 88

natural products, and alternative treatments, 120  
 nerve fibers, and nociception, 13  
 neurobiology, of pain: and allodynia, 26; and drug mechanism hypotheses, 45; and endocannabinoid deficiency hypothesis, 44; and gray matter hypothesis, 41–43; and hyperalgesia, 25, 28; and inflammatory pain, 28; and neuropathic pain, 27, 29–30; and nociception, 12–17, 19, 22–23, 31; overview of, 11; and peripheral sensitization, 32–33  
 neuropathic pain: and “abnormal” pain, 29–30; definition of, 27; difference between acute pain and, 22; and drug mechanism hypotheses, 45; and duloxetine, 98; risk factors for, 51. *See also* diabetic peripheral neuropathic pain

neurotransmitters, and nociception, 16–17, 19  
 NMDA-blockers, 121  
 nociception: activity-dependent in pain pathways, 19; definition of, 12; and excessive activity, 31; and nerve fibers, 13; and “normal” pain, 22–23; and perception, 17; and segmental central sensitization, 35; and transduction, 14–15; and transmission, 16  
 non-compliance, of patient with treatment, 124  
 non-steroidal anti-inflammatory drugs (NSAIDs), 86  
 norepinephrine: chronic pain and deficient, 29; and serotonin norepinephrine reuptake inhibitors, 97; and tricyclic antidepressants, 87. *See also* norepinephrine transporter  
 norepinephrine reuptake inhibitors (NRIs), and back pain, 72  
 norepinephrine transporter (NET), 100, 102, 104  
 nucleus accumbens, and fibromyalgia, 60

obsessive-compulsive disorder, and fibromyalgia, 66  
 older patients, prevalence of pain in, 2  
 opiates: analgesic effects from, 83; long term effects of use, 84; pain patients and “opiate problem,” 53–55  
 osteoarthritis, 71, 87  
 oxcarbazepine, 74, 110–111  
 pain: consequences of inadequate treatment for, 8; impact and cost of, 1, 4–7; learning and “unlearning” of, 38–39; patient perception of, 3, 127; prevalence of, 1, 2; risk factors for disability from, 9. *See also* acute pain; chronic pain; cognitive function; drugs; neurobiology; neuropathic pain; pain disorders; patients; symptoms; treatment

- pain disorders: overview of, 57;  
 preemptive treatment of, 37; treatment  
 of as chronic disease, 128. *See also*  
 back pain; chronic pelvic pain;  
 complex regional pain syndrome;  
 diabetic peripheral neuropathic pain;  
 fibromyalgia; osteoarthritis;  
 temporomandibular joint disorder;  
 trigeminal neuralgia
- panic disorder, and fibromyalgia, 66
- parabrachial nucleus, 18
- patients: and directed history, 50; and  
 laboratory tests, 52; and  
 non-compliance, 124; and "opiate  
 problem," 53–55; overview of, 47;  
 perception of and perspective on pain  
 by, 3, 17, 127; and physical  
 examination, 51; and presentation of  
 pain, 48; and ruling out of other  
 diagnoses, 49. *See also* treatment
- pelvic pain, 76
- perception, of pain, 3, 17
- periaqueductal gray: and cannabinoids,  
 44; chronic pain and changes in, 41;  
 and nociception, 17, 18. *See also*  
 gray matter
- peripheral nervous system, and pain  
 disorders, 57. *See also* peripheral  
 sensitization
- peripheral pain, clinical differences  
 between central pain and, 24. *See  
 also* diabetic peripheral neuropathic  
 pain
- peripheral sensitization: and  
 anticonvulsants, 107; and ectopic  
 activity, 32; and ephaptic cross-talk,  
 33. *See also* peripheral nervous system
- personal relationships, impact of pain  
 on, 4
- phantom pain, 40
- phenytoin, 74, 118
- physical examination, 51
- polypharmacy, and complex regional  
 pain syndrome, 70
- postherpetic neuralgia (PHN), 57
- postherpetic neuropathic pain (PHN), 73
- posttraumatic stress disorder (PTSD):  
 and fibromyalgia, 66, 68; pain as  
 symptom of, 79; and  
 temporomandibular joint disorder, 75
- precipitant contributory factors, for  
 disability from pain, 9
- preemptive treatment, of pain disorders,  
 37
- pregabalin, 74, 90, 94–95
- premorbid risks, for disability from pain,  
 9
- presymptomatic treatment, 37
- prevalence: of comorbidity of  
 fibromyalgia with mood and anxiety  
 disorders, 66; of pain, 1, 2; of pain  
 comorbid with depression, 4; of pain  
 as symptom of anxiety and mood  
 disorders, 78
- primary afferent neurons, 13, 14
- prodromal treatment, and stress  
 sensitization, 37
- psychiatric disorders, and chronic  
 neuropathic pain, 24. *See also* anxiety  
 disorders; bipolar disorder;  
 depression; mood disorders;  
 obsessive-compulsive disorder; panic  
 disorder; posttraumatic stress disorder
- rapid eye movement (REM) sleep  
 disorder, 64
- rating scales, 125–26
- reward circuits, and action of opiates, 84
- risk factors: for back pain, 72; for  
 disability from pain, 9; for neuropathic  
 pain disorder, 51
- S-adenosylmethionine, 120
- Schwann cells, 32
- segmental central sensitization, 34–35
- serotonin: and neuropathic pain, 30;  
 and serotonin norepinephrine reuptake  
 inhibitors, 97; and tricyclic  
 antidepressants, 87. *See also*  
 serotonin transporter
- serotonin norepinephrine reuptake  
 inhibitors (SNRIs), 96–105

- serotonin transporter (SERT), 100  
 shingles, 73  
 side effects: of carbamazepine, 109; of desvenlafaxine, 105; of duloxetine, 99; of gabapentin, 93; of lamotrigine, 113; of milnacipran, 101; of oxcarbazepine, 111; of pregabalin, 95; of topiramate, 115; of tricyclic antidepressants, 88; of venlafaxine, 103; of zonisamide, 117  
 sleep and sleep disorders, and fibromyalgia, 64  
 social phobia, 66  
 society, impact and costs of pain, 1, 6  
 somatosensory cortex, 17  
 spinal cord: and fibromyalgia, 60; and nociception, 13, 15–16  
 spinobulbar and spinothalamic tracts, 17  
 stimulants, 119  
 strength training, 129  
 stress sensitization, 37  
 striatum, and fibromyalgia, 60  
 substance abuse: and opiates, 53, 84; and patient non-compliance, 124  
 subsyndromal treatment, 37  
 subthreshold pain response, 19  
 suicide, pain as reason for considering, 4  
 supra-segmental central sensitization, 36  
 symptoms: central sensitization and increase in, 34; of fibromyalgia, 60; pain as concomitant form of, 77–79. *See also* cognitive function
- temporal lobe, 18  
 temporomandibular joint disorder (TMJ), 58, 75  
 tender points, and fibromyalgia, 58–59, 68  
 thalamocortical pathway, 17  
 thalamus, 17, 60  
 thyroid function (TSH), 52  
 tiagabine, 118  
 tolerance, and long term effects of opiates, 84  
 topiramate, 74, 114–15
- transduction, and nociception, 14–15  
 transmission, and nociception, 16  
 treatment, of pain and pain disorders: and communication, 130; of complex regional pain syndrome, 70; consequences of inadequate, 8; and integrated care system, 128; legal issues in, 124; non-pharmaceutical adjunct forms of for chronic pain, 129; overview of, 123; stress sensitization and preemptive, 37; and under-treatment, 8, 124. *See also* drugs; patients
- tricyclic antidepressants, 87–89  
 trigeminal neuralgia, 48, 74, 108  
 triptans, 120  
 tuberomammillary nucleus, 65
- vanilloid 1 (VR1) receptor, 15  
 venlafaxine, 102–103  
 veterans, and comorbidity of posttraumatic stress disorder and chronic pain, 79  
 voltage-sensitive calcium channels (VSCCs): and alpha 2 delta ligands, 90, 91; and anticonvulsants, 107; and nociception, 15  
 voltage-sensitive ion channel depolarization, 14, 19  
 voltage-sensitive sodium channels (VSSCs): and anticonvulsants, 107; and nociception, 14–15; and peripheral sensitization, 32; and tricyclic antidepressants, 88  
 voxel-based morphometry (VBM), 41
- wind-up, and segmental central sensitization, 35  
 withdrawal, from venlafaxine, 102  
 women, and fibromyalgia, 67  
 work and workplace, and impact of pain, 4, 6
- XP-13512, 92
- zonisamide, 116–17